Latest Breaking News On - Chris maggos - Page 1 : vimarsana.com

AC Immune SA: AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 - AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering

AC Immune Reports First Quarter 2024 Financial Results and

STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder

PolTREG S.A.: PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab

PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab

PolTREG S.A.: PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland

PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland

Gdańsk, Poland – 11 March 2024 – PolTREG S.A. , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it has received CGMP.

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologies Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its preci

AC Immune SA: AC Immune Announces Upcoming Presentations at AD/PD 2024

PolTREG appoints Dan Shelly as Chief Business Development Officer